Intelligence Report · ~10 min read

Hospira Intelligence Report

Pfizer · Anesthesia · Local Anesthetic · Approved

Type

Asset Intelligence Report

Generated

Jul 24, 2026

Confidence

Moderate Confidence · 69%

Evidence

26 items

Sources

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Lidocaine Hydrochloride by Hospira is significant as it may strengthen Hospira's competitive position in the local anesthetic market. Companies with similar products should reassess their strategies in light of this development. Regulatory context from FDA (FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

Key Developments

Material intelligence events ranked by strategic relevance.

insightJul 1, 2026
Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia
Intelligence brief refreshed — The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Lidocaine Hydrochloride by Hospira is significant as it may strengthen Hospira's competitive position in the local anesthetic market. Companies with similar products should reassess their strategies in light of this development. Regulatory context from FDA (FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).
View detail
watchJul 1, 2026
Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia
Monitor the final approval and market entry timeline for Lidocaine Hydrochloride by Hospira, as delays could impact competitive strategies.
View detail
watchJul 1, 2026
Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia
Watch for any shifts in competitor strategies in response to Hospira's approval, particularly regarding product positioning and marketing efforts.
View detail
watchJul 1, 2026
Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia
Keep an eye on ongoing clinical trials that may influence the safety and efficacy narrative surrounding local anesthetics.
View detail
regulatoryJul 1, 2026
FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)
Application ANDA218722. Sponsor: ALKEM LABS LTD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: SOLRIAMFETOL HYDROCHLORIDE.
View detail
regulatoryJul 1, 2026
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
Application NDA201194. Sponsor: VISTAPHARM LLC. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: OXYCODONE HYDROCHLORIDE.
View detail
regulatoryJul 1, 2026
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
Application NDA200534. Sponsor: GENUS LIFESCIENCES. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: OXYCODONE HYDROCHLORIDE.
View detail
regulatoryJul 1, 2026
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
Application NDA200535. Sponsor: GENUS LIFESCIENCES. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: OXYCODONE HYDROCHLORIDE.
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Portfolio teams should assess the competitive landscape for local anesthetics and consider strategic positioning against Hospira's offering. The strongest clinical anchor is Postoperative Cognitive Function After Different Anesthetic Techniques in Obese Patients (ClinicalTrials.gov), moderate corpus alignment. In Anesthesia · Local Anesthetic, 8 regulatory and 1 competitive items passed relevance filtering for Hospira. This becomes more urgent if Monitor for the final approval and market entry timeline for Lidocaine Hydrochloride by Hospira. Timeline shift beyond mid term would change urgency. A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)
FDA
Source: FDA
View evidence
FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)
FDA
Source: FDA
View evidence
FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)
FDA
Source: FDA
View evidence
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
FDA
Source: FDA
View evidence
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDA
Source: FDA
View evidence
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDA
Source: FDA
View evidence
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDA
Source: FDA
View evidence
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDA
Source: FDA
View evidence
FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)
high relevance
Application ANDA040078. Sponsor: HOSPIRA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LIDOCAINE HYDROCHLORIDE.
Source: FDA
View evidence
FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)
high relevance
Application ANDA083158. Sponsor: HOSPIRA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LIDOCAINE HYDROCHLORIDE.
Source: FDA
View evidence
FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)
high relevance
Application ANDA083158. Sponsor: HOSPIRA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LIDOCAINE HYDROCHLORIDE.
Source: FDA
View evidence
FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)
high relevance
Application ANDA217238. Sponsor: MICRO LABS. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: PROPRANOLOL HYDROCHLORIDE.
Source: FDA
View evidence
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
high relevance
Application ANDA220869. Sponsor: RUBICON RESEARCH. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: DEXTROMETHORPHAN HYDROBROMIDE, PROMETHAZINE HYDROCHLORIDE.
Source: FDA
View evidence
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
high relevance
Application ANDA218567. Sponsor: MACLEODS PHARMS LTD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: BUPROPION HYDROCHLORIDE.
Source: FDA
View evidence
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
high relevance
Application ANDA079148. Sponsor: INDICUS PHARMA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: METFORMIN HYDROCHLORIDE.
Source: FDA
View evidence
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
high relevance
Application NDA200535. Sponsor: GENUS LIFESCIENCES. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: OXYCODONE HYDROCHLORIDE.
Source: FDA
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

FDA Grants AP Status for Lidocaine Hydrochloride ANDA040078
Regulatory Approval

Insights

Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia
Anesthesia · Local Anesthetic

Companies

Pfizer
Sponsor

Executive Summary

Key Developments

Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

FDA AP — SOLRIAMFETOL HYDROCHLORIDE (ORIG)

FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

Strategic Implications

Supporting Evidence

FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)

FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)

FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)

FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)

FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)

FDA AP — BUPROPION HYDROCHLORIDE (ORIG)

FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)

FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)

FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)

FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)

FDA AP — PROPRANOLOL HYDROCHLORIDE (ORIG)

FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)

FDA AP — BUPROPION HYDROCHLORIDE (ORIG)

FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)

FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

Related Intelligence

Signals

Insights

Companies